Discloses U.S. FDA Pre-Approval Inspection completion at Indoco's Aurangabad testing facility.
Inspection conducted from April 8-10, 2026, concluded with zero Form 483 observations.
Filing is a mandatory SEBI LODR Regulation 30 disclosure to the stock exchanges.